Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Breyanzi® (lisocabtagene maraleucel) – New orphan drug approval

The FDA announced the approval of Bristol-Myers Squibb Breyanzi (lisocabtagene maraleucel), for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. February 5, 2021

Tepmetko® (tepotinib) – New drug approval

EMD Serono announced the FDA approval of Tepmetko (tepotinib), for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. February 3, 2021

Ukoniq™ (umbralisib) – New orphan drug approval

TG Therapeutics announced the FDA approval of Ukoniq (umbralisib), for the treatment of adult patients with: (1) relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen or (2) relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. February 5, 2021

Xeljanz®, Xeljanz XR (tofacitinib) – Safety update

The FDA announced that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. February 4, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.